biotech.today

Details

  • ●Modalities: small molecules
  • ●Therapeutic areas: fibrosis, oncology, immunology, CNS
  • ●Key targets: TNIK, USP1, KAT6A, undisclosed oncology targets
  • ●Indications: idiopathic pulmonary fibrosis, solid tumors, inflammatory bowel disease, COVID-19
  • ●Funding: $400M+

Partners & investors

  • Warburg Pincus· Investor
  • Qiming Venture Partners· Investor
  • B Capital Group· Investor
  • Pavilion Capital (Temasek)· Investor

Key considerations

  • ●AI tools in use: PandaOmics (target discovery), Chemistry42 (generative chemistry), InClinico (clinical trial prediction), Pharma.AI platform
  • ●First AI-discovered + AI-designed drug in Phase 2
  • ●Menarini licensing deal >$500M total potential (2024)
  • ●$110M Series E (March 2025)

Pipeline

  • Preclinical2
  • Phase 11
  • Phase 21
Get live updates on Insilico Medicine’s hiring, filings, and partnerships. Follow in BT Pro →
Source: Company website, SEC / Companies House filings, press releases, Crunchbase · biotech.today analysis (Apr 2026)

Key people

Alex Zhavoronkov

Founder & CEO

aging biologygenerative AIcomputational drug discovery

Feng Ren

Co-CEO & Chief Scientific Officer

medicinal chemistryAI drug designclinical development
Visit website →LinkedIn →